Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847402 | 0.89 | USP30 (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL12158 | 0.89 | USP30 (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL10173079 | 0.83 | CCNB2 (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL6783942 | 0.83 | HSD17B10 (0.53) | KMT2ANPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL856144 | 0.82 | TBXA2R (0.39) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL4527113 | 0.81 | CCNB2 (0.38) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL481590 | 0.81 | BACE1 (0.41) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL29967119 | 0.80 | BACE1 (0.38) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL28877791 | 0.80 | BACE1 (0.38) | CCNB2CDK1CCNB1GSK3BCCNB3 | |
| SCHEMBL133464 | 0.80 | ALDH1A1 (0.57) | MAPTGAANR1H2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-107531683-B | USP7 inhibitor compounds and methods of use | 豪夫迈·罗氏有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3271333-B1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3271333-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573899-B2 | USP7 inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2016150800-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015140717-A9 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | CCNB2 3536/4885CDK1 197/4885CCNB1 2415/4885 |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | CCNB2 1133/4885CDK1 512/4885CCNB1 808/4885 |
| US-20160272588-A1 | USP7 INHIBITOR COMPOUNDS AND METHODS OF USE | USP7, UBA7, USP1 | CCNB2 1133/4885CDK1 378/4885CCNB1 1313/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | CCNB2 1162/4885CDK1 130/4885CCNB1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.